By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Janssen Pharmaceutical K.K. 

Takanawadai Daiichi-Seimei Building 1-5
Higashi-Gotanda 3-chome
Shinagawa-ku    141  Japan
Phone: 81-3-3445-221 Fax: n/a



Company News
AstraZeneca PLC (AZN) to Co-Promote Janssen Pharmaceutical K.K.'s Prostate Cancer Drug in Japan 10/11/2013 6:57:15 AM
Janssen Pharmaceuticals, Inc. Confirms XARELTO® is as Effective as the Standard of Care in Treatment of DVT and PE 9/20/2013 7:02:56 AM
Johnson & Johnson (JNJ) Handed a Federal Subpoena Over Nucynta Marketing 8/5/2013 7:19:31 AM
Janssen Pharmaceutical K.K. and Taiwan University Team Up to Fight Hepatitis B 6/5/2013 9:06:40 AM
Janssen Pharmaceutical K.K. Opens R&D Center in Shanghai 2/6/2013 10:21:08 AM
NGM Biopharmaceuticals, Inc., Janssen Pharmaceutical K.K. Form Alliance for Undisclosed Amount 1/3/2013 8:05:32 AM
Evotec AG (EVTG.F), Janssen Pharmaceutical K.K. Sign License Agreement for Up to $175 Million 12/17/2012 7:26:16 AM
FDA Approves Janssen Pharmaceutical K.K.'s NUCYNTA® ER (tapentadol) Extended-Release Oral Tablets for Neuropathic Pain 8/29/2012 7:01:54 AM
Janssen Pharmaceutical K.K. Release: Phase 3 Data Show NUCYNTA® ER (tapentadol) Extended-Release Tablets Provide Pain Management for Patients with Diabetic Peripheral Neuropathy (DPN) 5/18/2012 10:55:53 AM
Watson Pharmaceuticals, Inc. (WPI) Reaches Settlement With Janssen Pharmaceutical K.K. Over ORTHO TRI-CYCLEN(R) LO 2/8/2012 10:55:13 AM